Sectors

GYRE
Gyre Therapeutics, Inc.
6.10
1 x 5.96
1 x 6.04
bid
ask
+
0.04
0.71%
10:02 AM
timesize
Ytd-13.55%
1y-15.58%
5.97
day range
6.10
5.44
52 week range
9.42
Open6.03Prev Close6.06Low5.97High6.10Mkt Cap553.83M
Vol2.42KAvg Vol93.84KEPS0.07P/E86.57Forward P/E25.22
Beta1.89Short Ratio21.22Inst. Own1.96%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning05-0750-d Avg6.34200-d Avg7.371yr Est0.00

GYRE News

Gyre Therapeutics Appoints Three New Members to its Board of Directors
globenewswire.com
Gyre Therapeutics Appoints Three New Members to its Board of Directors

SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or

Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm
newsfilecorp.com
Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term G

Newtown Square, Pennsylvania--(Newsfile Corp. - May 27, 2026) - Kaskela Law LLC is investigating Gyr

New Strong Sell Stocks for May 27th
zacks.com
New Strong Sell Stocks for May 27th

GYRE, FSUN and AKZOY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2026.

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
globenewswire.com
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-I

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or

Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates
zacks.com
Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates

Gyre Therapeutics, Inc. (GYRE) came out with a quarterly loss of $0.05 per share versus the Zacks Co

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
globenewswire.com
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update

Q1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
globenewswire.com
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated

Post-closing combined company has revenue-producing commercial asset and a robust pipeline of produc

Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
globenewswire.com
Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) fo

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (N

Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates
zacks.com
Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates

Gyre Therapeutics, Inc. (GYRE) came out with quarterly earnings of $0.04 per share, missing the Zack

Earnings Scheduled For March 12, 2026
benzinga.com
Earnings Scheduled For March 12, 2026

Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business

Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range

Head-To-Head Contrast: Gyre Therapeutics (NASDAQ:GYRE) versus Tenax Therapeutics (NASDAQ:TENX)
defenseworld.net
Head-To-Head Contrast: Gyre Therapeutics (NASDAQ:GYRE) versus Tenax Therapeutics (NASDAQ:TENX)

Tenax Therapeutics (NASDAQ: TENX - Get Free Report) and Gyre Therapeutics (NASDAQ: GYRE - Get Free R

Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline
globenewswire.com
Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Plat

Acquisition will create a U.S.- and China-based fully integrated biopharmaceutical company with reve

Analyzing Gyre Therapeutics (NASDAQ:GYRE) and ImmunityBio (NASDAQ:IBRX)
defenseworld.net
Analyzing Gyre Therapeutics (NASDAQ:GYRE) and ImmunityBio (NASDAQ:IBRX)

ImmunityBio (NASDAQ: IBRX - Get Free Report) and Gyre Therapeutics (NASDAQ: GYRE - Get Free Report)

Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting
globenewswire.com
Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority

Gyre Pharmaceuticals completed a Pre-NDA meeting with China's CDE, which agreed that the existing Ph

Gyre Therapeutics, Inc. (GYRE) Q3 Earnings Surpass Estimates
zacks.com
Gyre Therapeutics, Inc. (GYRE) Q3 Earnings Surpass Estimates

Gyre Therapeutics, Inc. (GYRE) came out with quarterly earnings of $0.06 per share, beating the Zack

Earnings Scheduled For November 7, 2025
benzinga.com
Earnings Scheduled For November 7, 2025

Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
globenewswire.com
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Busines

Net income of $5.9 million and $11.2 million for the three and nine months ended September 30, 2025,

New Strong Sell Stocks for Oct. 17th
zacks.com
New Strong Sell Stocks for Oct. 17th

GYRE, DAR and CRLBF have been added to the Zacks Rank #5 (Strong Sell) List on October 17, 2025.

Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
globenewswire.com
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidon

SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Nasdaq: GYRE), an innovative, commer

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
globenewswire.com
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for

SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (Nasdaq: GYRE), an innovativ

benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session

Elastic, Applied Digital, Eightco Holdings And Other Big Stocks Moving Higher On Friday
benzinga.com
Elastic, Applied Digital, Eightco Holdings And Other Big Stocks Moving Higher On Friday

Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
globenewswire.com
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovati

benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session